Blood Reviews
Volume 20, Issue 1 , Pages 43-50 , January 2006

Mobilizing the older patient with myeloma

  • Michele Cottler-Fox

      Affiliations

    • Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 501 603 1941; fax: +1 501 686 8887.
    • ,
  • Tsvee Lapidot

      Affiliations

    • Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel 76100
    • Tel.: +972 8 931 2481; fax: +972 8 934 4141.

References 

  1. Cottler-Fox M, Lapidot T, Petit I, et al. Stem Cell Mobilization. ASH Educat Progr. 2003;419–437
  2. Papayannopolou T. Mechanisms of stem-/progenitor–cell mobilization: the anti-VLA-4 paradigm. Semin Hematol. 2000;37:11–18
  3. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules cytokines and stromal cells. Exp Hematol. 2002;30:973–981
  4. Schwarz B, Bhandoola A. Circulating hematopoietic progenitors with T lineage potential. Nat Immunol. 2004;5(9):953–960
  5. Abkowitz J, Robinson A, Kale S, et al. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood. 2003;102:1249–1253
  6. Bishop N, Williams D, Compton J, et al. Osteoporosis in severe congenital neutropenia treated with granulocte colony-stimulating factor. Br J Haematol. 1995;89:927–928
  7. Takamatsu Y, Simmons P, Moore R, et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood. 1998;92:3465–3473
  8. Schots R, VanRiet I, Damianos S, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be predicted by apheresis. Bone Marrow Transplant. 1996;17:509–515
  9. Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor cell dose with engraftment after high-dose chemotherapy in patients with germ–cell cancer. J Clin Oncol. 1996;14:1114–1121
  10. Mohle R, Murea S, Pforsich M, Witt B, Haas R. Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood. Vox Sang. 1996;71:90–96
  11. Ford C, Chan K, Reilly W, Peterson F. An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion. 2003;43:622–625
  12. Moncada V, Bolan C, Yau Y, Leitman S. Analysis of PBPC yields during large volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion. 2003;43:495–501
  13. Weaver C, Birch R, Schwartzberg L, et al. CD34+ content of peripheral blood progenitor cells is the single most powerful predictor of recovery kinetics in patients receiving myeloablative high-dose chemotherapy and PBPC infusion. Blood. 1994;84:1388a
  14. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588–596
  15. Brecher M, Sims L, Schmitz J, Shea T, Bentley S. North American multicenter study on flow cytometry of CD34+ hematopoietic stem cells. J Hematotherapy. 1996;5:227–236
  16. O’Connell B, Ng Y, Rapoport A, Fassas A, Tricot G, Cottler-Fox M. Maximizing collection of human peripheral blood progenitor cells while minimizing the number of aphereses. Blood. 1999;94:4749a
  17. Yu J, Leisenring W, Fritschle W, et al. Enumeration of HPC in mobilized peripheral blood with the Sysmex SE-9500 predicts final CD34+ cell yield in the apheresis collection. Bone Marrow Transplant. 2000;25:1157–1164
  18. Yin A, Miragha S, Zanjani E, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–5012
  19. Nakauchi H. Hematopoietic stem cells: are they CD34 positive or CD34 negative?. Nature Medicine. 1998;4:1009–1010
  20. Storms R, Trujillo A, Springer J, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. PNAS USA. 1999;96:9118–9123
  21. Balber A, Gentry C, Pritchard C, et al. ABC-mediated efflux of ALDH reaction product: implications for enumeration and isolation of blood progenitor cells. Biol Blood Marrow Transplant. 2003;9:231a
  22. Morstyn G, Campbell L, Duhrsen U, et al. Clinical studies with G-CSF in patients receiving cytotoxic chemotherapy. Behring Inst Mitt. 1988;83:234–239
  23. Morstyn G, Lieschke G, Sheriden W, et al. Pharmacology of the colony-stimulating factors. Trends Pharmacol Sci. 1989;10:154–159
  24. Layton J, Hockman H, Sheriden W, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood. 1989;74:1303–1307
  25. Hillyer C, Lackey D, Hart K, et al. CD34+ progenitors and CFU-GM are recruited during large-volume leukapheresis and concentrated by counterflow centrifugal elutriation. Transfsion. 1993;33:316–321
  26. Gorlin J, Vamvakas E, Cooke E, et al. Large volume leukapheresis in pediatric patients: processing more blood diminishes the apparent magnitude of intra-apheresis recruitment. Transfusion. 1996;36:879–885
  27. Kroger N, Sonnenberg S, Cortes-Deriks L, Freiberger P. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with recombinant human granulocyte stimulating factor (lenograstim) in healthy volunteers: an intrindividual cross-over study. Blood. 2003;102(11):3547a
  28. Morris C, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413–423
  29. Bensinger W, Buckner W, Rowley S, Storb R, Appelbaum F. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant. 1996;17:S19–S21
  30. Shimoda K, Okamura S, Haarada N, Kondo S, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest. 1993;91:1310–1313
  31. Becker P, Wagle M, Matous , et al. Spontaneous splenic rupture following administration of G-CSF: occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45–49
  32. Stroncek D, Shawker T, Folman D, Leitman S. G-CSF induced spleen size changes in PBPC donors. Transfusion. 2003;43:609–613
  33. Baloguer H, Galmes A, Ventayol G, et al. Splenic rupture after granulocyte-colony stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion. 2004;44:1260–1261
  34. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of G-CSF mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996;36:590–595
  35. Stroncek D, Clay M, Petzold M, et al. Treatment of normal individuals with G-CSF: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36:601–610
  36. Bolwell B, Goormastic M, Yanssems T, et al. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and enhancing recovery after autologous bone marrow transplant. Bone Marrow Transplant. 1997;14:913–918
  37. Peters W, Rosner G, Ross M, et al. Comparative effects of GM-CSF and G-CSF on priming peripheral blood progenitor cells after chemotherapy. Blood. 1993;81:1709–1719
  38. Richard C, Baro J, Bello-Fernandez C, Hermida G, Calavia J, Olalla I, et al. Recombinant human GM-CSF administration after autologous BMT for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant. 1995;15:721–726
  39. Richard C, Alsar M, Calavia J, et al. Recombinant human GM-CSF enhances T cell mediated cytotoxic function after autologous bone marrow transplantation for hematological malignancies. Bone Marrow Transplant. 1993;11:473–478
  40. Spitler L, Grossbard M, Ernstoff M, et al. Adjuvant therapy of Stage III and IV malignant melanoma using GM-CSF. J Clin Oncol. 2000;18:1614–1621
  41. Slavin S, Mumcuoglu M, Landsberg-Weisz A, Kedar E. The use of recombinant cytokines for enhancing immuno-hematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide. Bone Marrow Transplant. 1989;4:459–464
  42. Avigan D, Wu Z, Gong J, et al. Selective in vivo mobilization with GM-CSF/G-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clinical Cancer Res. 1999;5:2735–2741
  43. Ho A, Young D, Maruyama M, et al. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs a combination of both. Exp Hematol. 1996;24:1460–1488
  44. Law P, Young D, Peterson S, Lane T, Ho A. Mobilization and collection of peripheral blood progenitor cells from normal subjects treated sequentially with GM-CSF and G-CSF. Blood. 1996;88:1578a
  45. Winter J, Lazarus H, Rodemaker A, et al. Phase I/II study of combined G-CSF and GM-CSF administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol. 1996;14:277–286
  46. Kiessinger A, Bishop M, Jackson J, et al. Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. Exp Hematol. 1995;23:609–612
  47. Facon T, Harousseau J, Maloisel F, et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood. 1999;128–225
  48. Steidl V, Fenk R, Kondakci M, et al. Transplantation of peripheral blood stem cells mobilized by single application of pegylated G-CSF in patients with multiple myeloma. Blood. 2003;102(11):3554a
  49. Fassas A, Cottler-Fox M, Calandra G, Tricot G. ASCO Annual Meeting. 2004;23:6643a
  50. Cottler-Fox M, Holley D, Whigham L, et al. Hematopoietic progenitor cell (HPC) mobilization after initial therapy of multiple myeloma including velcade: ability to collect HPC as a function of velcade dosing. Blood. 2004;104(11):2884a
  51. Miclea J, Makki J, Lefrere F, et al. Successful PBPC harvesting with G-CSF alone a short time after previous mobilizataion failure by both chemotherapy and hematopoietic growth factors. Blood. 1999;94:1465a
  52. Buddharaju L, Tricot G, Rapoport A, Fassas A, O’Connell B, Cottler-Fox M. Successful mobilization of CD34+ cells using GM-CSF and G-CSF in patients with mobilization failure after initial chemotherapy and cytokine combination. Blood. 1999;94:1465a
  53. Watts M, Ings S, Flynn M, et al. Remobilization of poor stem cell mobilizers is clinically worthwhile. Blood. 1999;94:1467a
  54. Schwella N, Braun A, Ahrens N, Rick O, Salama A. Leukapheresis after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft. Transfusion. 2003;43:259–264
  55. Schenkane D, O’Connor C, Morelli J, et al. A randomized trial of two different priming methods for stem cell mobilization in patients with relapsed Hodgkin’s disease and Non-Hodgkin’s lymphoma. Blood. 1999;94:1460a
  56. Cottler-Fox M, Love-Turner H, Holley D, et al. Hematopoietic progenitor/stem cell mobilization after prior autologous blood and marrow transplant. Blood. 2003;102(11):3553a
  57. Goldschmidt H, Hegenbart U, Haas R, Hunstein W. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide and G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 1996;17:691–697
  58. Meisenberg B, Miller W, McMillan R. Efficient and predictable mobilization of peripheral blood stem cells with low-dose cyclophosphamide followed by sequential GM-CSF and G-CSF. Transfusion. 1998;38:209–215
  59. Olivieri A, Offidam M, Cantori I, et al. Addition of erythropoietin to G-CSF after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplantation. 1995;16:765–770
  60. Hollmig K, Stover J, Cottler-Fox M, et al. Collection of peripheral blood stem cells in 668 patients with multiple myeloma treated on Total Therapy II (UARK 98-026). Blood. 2004;104(11):

PII: S0268-960X(05)00040-8

doi: 10.1016/j.blre.2005.06.001

Blood Reviews
Volume 20, Issue 1 , Pages 43-50 , January 2006

Article Tools